Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | HTR1D | P28221 | 4/20 | 0.41 |
| ▸ | HTR1B | P28222 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305414 | 0.90 | MAPT (0.45) | MTNR1AMTNR1BHTR1AHTR1DHTR1B | |
| SCHEMBL124046 | 0.86 | MTNR1A (0.47) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL30064848 | 0.85 | MTNR1A (0.40) | MTNR1AMTNR1BHTR1AHTR1DHTR1B | |
| SCHEMBL7804729 | 0.84 | CA1 (0.39) | HTR1AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL6361624 | 0.83 | HNF4A (0.43) | MTNR1AMTNR1BKDM4EMEN1ALDH1A1 | |
| SCHEMBL16690522 | 0.83 | HTR1A (0.41) | HTR1AHTR1DHTR1BHTR2CHTR7 | |
| SCHEMBL8499219 | 0.82 | L3MBTL1 (0.50) | HSD11B1L3MBTL1KDM4EMEN1TSHR | |
| SCHEMBL3073070 | 0.82 | ADORA2A (0.40) | MTNR1AMTNR1BMEN1ALDH1A1MAPT | |
| SCHEMBL9939378 | 0.82 | SLC2A1 (0.42) | MTNR1AMTNR1BHSD11B1L3MBTL1KDM4E | |
| SCHEMBL6935409 | 0.81 | CA12 (0.55) | L3MBTL1MEN1ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352801-B1 | ELECTROACTIVE MATERIALS | DU PONT (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9099653-B2 | Electroactive materials | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-9099653-B2 | Electroactive materials | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-8420232-B2 | Binaphthyl-arylamine polymers | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420232-B2 | Binaphthyl-arylamine polymers | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8053604-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20100187506-A1 | ELECTROACTIVE MATERIALS | LG CHEM, LTD. (KR) | 2010-07-29 | — | — | US | disclosed |
| US-20100187506-A1 | ELECTROACTIVE MATERIALS | LG CHEM, LTD. (KR) | 2010-07-29 | — | — | US | disclosed |
| US-20100187507-A1 | ELECTROACTIVE MATERIALS | LG CHEM, LTD. (KR) | 2010-07-29 | — | — | US | disclosed |
| US-20100187507-A1 | ELECTROACTIVE MATERIALS | LG CHEM, LTD. (KR) | 2010-07-29 | — | — | US | disclosed |
| WO-2010065497-A2 | ELECTROACTIVE MATERIALS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065700-A2 | ELECTROACTIVE MATERIALS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | SPERA PHARMA, INC. (JP) | 2010-05-20 | — | — | US | disclosed |
| US-7678942-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| EP-1452537-B1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | H1-10, ITPA, RER1 | MTNR1A 4694/4885MTNR1B 4254/4885HTR1A 3782/4885 |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | BACE1, H1-10, PRMT1 | MTNR1A 1703/4885MTNR1B 1833/4885HTR1A 2469/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | MTNR1A 4711/4885MTNR1B 4275/4885HTR1A 3788/4885 |
| US-20100187506-A1 | ELECTROACTIVE MATERIALS | ARL1, ITGA1, ITGB1 | MTNR1A 616/4885MTNR1B 624/4885HTR1A 796/4885 |
| US-20100187507-A1 | ELECTROACTIVE MATERIALS | ESR2, NR3C2, AR | MTNR1A 233/4885MTNR1B 780/4885HTR1A 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.